Cargando...
Predicting Amyloid Burden to Accelerate Recruitment of Secondary Prevention Clinical Trials
BACKGROUND: Screening to identify individuals with elevated brain amyloid (Aβ+) for clinical trials in Preclinical Alzheimer’s Disease (PAD), such as the Anti-Amyloid Treatment in Asymptomatic Alzheimer’s disease (A4) trial, is slow and costly. The Trial-Ready Cohort in Preclinical/Prodromal Alzheim...
Gardado en:
| Publicado en: | J Prev Alzheimers Dis |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
2020
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7745538/ https://ncbi.nlm.nih.gov/pubmed/32920622 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.14283/jpad.2020.44 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|